IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies

VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.